Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 6/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28086194 | 1.00 | CXCR1 (0.47) | CXCR1CXCR2MAPTKMT2AKCNK3 | |
| SCHEMBL18556234 | 0.88 | MAPT (0.43) | CXCR1CXCR2MAPTKMT2AKCNK3 | |
| SCHEMBL14904771 | 0.88 | GAA (0.47) | CXCR1CXCR2MAPTKMT2AKDM4E | |
| SCHEMBL14904738 | 0.85 | MAPT (0.56) | CXCR1CXCR2MAPTKMT2AKDM4E | |
| SCHEMBL18556235 | 0.85 | MAPT (0.56) | CXCR1CXCR2MAPTKMT2AKDM4E | |
| SCHEMBL14904773 | 0.84 | CXCR1 (0.49) | CXCR1CXCR2KCNK3GAACNR1 | |
| SCHEMBL14895239 | 0.83 | SMN1; SMN2 (0.48) | CXCR1CXCR2MAPTKMT2A | |
| SCHEMBL14895238 | 0.83 | SMN1; SMN2 (0.48) | CXCR1CXCR2MAPTKMT2A | |
| SCHEMBL16144470 | 0.81 | KMT2A (0.50) | MAPTKMT2ALMNAGAA | |
| SCHEMBL7979807 | 0.77 | KMT2A (0.54) | MAPTKMT2ALMNACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
| CN-103906738-B | For treating new dibasic 3,4-diaminourea-3-cyclobutane-1,2-dione compounds of chemokine mediated disease | 高德美研究及发展公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2771329-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-03-16 | — | — | EP | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2013061004-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCR1, CCL11 | CXCR1 10/4885CXCR2 9/4885MAPT 3529/4885 |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCL11, CCR1 | CXCR1 11/4885CXCR2 9/4885MAPT 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.